This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
by Zacks Equity Research
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride
by Zacks Equity Research
MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride have been highlighted in this Screen of The Week article.
5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes
by Supriyo Bose
MPLX, LDOS, JAZZ, FTNT and PPC are some of the stocks with high ROE to profit from as markets falter on tariff concerns.
4 Top PEG Stocks Based on GARP Approach to Smart Investing
by Urmimala Biswas
Here are four discounted PEG stocks, JAZZ, FMS, DAN and ITRI, which qualify our screening criteria.
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
by Ekta Bagri
A recent regulatory setback has hit Harmony Biosciences stock. We recommend prospective investors to wait for a while before turning positive.
Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 38.9% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
JAZZ or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
JAZZ vs. ILMN: Which Stock Is the Better Value Option?
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
by Zacks Equity Research
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.
Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025
by Bryan Hayes
Despite a correction to begin the year, there are a few pockets of the market that are working.
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
by Zacks Equity Research
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Jazz Pharmaceuticals and Boston Beer Company have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Jazz Pharmaceuticals and Boston Beer Company are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: Jazz Pharmaceuticals (JAZZ)
by Bryan Hayes
The company boasts a strong drug portfolio with a primary focus in the areas of neuroscience and oncology.
Finding Great Momentum Stocks to Buy in March During the Selloff
by Benjamin Rains
Today we explore a screen that helps investors find surging stocks trading near fresh highs in early March amid the broader stock market selloff.
4 Discounted PEG Stocks Offering the Best Returns to Value Investors
by Urmimala Biswas
Here we present four discounted PEG stocks that qualify our screening criteria, TAP, BMRN, DVN and JAZZ.
Corcept Shares Rise More Than 55% in 6 Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well.
The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
by Zacks Equity Research
Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals are included in this Analyst Blog.
Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
by Zacks Equity Research
CMRX and JAZZ are in the spotlight this week following an acquisition agreement.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
by Zacks Equity Research
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
by Zacks Equity Research
JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.
Beat Market Volatility With 4 Low-Beta Stocks: PGR, PSO, TXO & JAZZ
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. PGR, PSO, TXO & JAZZ are well-poised to gain.